Formulation and optimization of nanosuspensions for enhancing simvastatin dissolution using central composite design

Dissolution Technologies

Volumn 18, Issue 3, 2011, Pages 40-45

  Pandya, Vikram M ^a   Patel, Jayvadan K ^b   Patel, Dhaval J ^c  

^a BS Patel Pharmacy College   (India)

^b NOOTAN PHARMACY COLLEGE   (India)

^c Shree Krishna Institute of Pharmacy   (India)

Author keywords

[No Author keywords available]

Indexed keywords

POLOXAMER; SIMVASTATIN; WATER; ZIRCONIUM OXIDE;

ARTICLE; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG SYNTHESIS; IN VITRO STUDY; PARTICLE SIZE; SUSPENSION;

EID: 80052707722     PISSN: 1521298X     EISSN: None     Source Type: Journal    
DOI: 10.14227/DT180311P40     Document Type: Article

References (17)

1. Seedher, N.; Bhatia, S. Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech 2003, 4 (3), 1-8.
2. Verma, S.; Gokhale, R.; Burgessa, D. J. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int. J. Pharm. 2009, 380, 216-222.
3. Jacobs, C.; Kayser, O.; Muller, R. H. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int. J. Pharm. 2000, 196, 161-164.
4. Liversidge, G.; Cundy, K. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazole in beagle dogs. Int. J. Pharm. 1995, 125, 91-97.
5. Muller, R. H.; Jacobs, C.; Kayser, O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect in the future. Adv. Drug Deliv. Rev. 2001, 47, 3-19.
6. Kakrana, M.; Sahooa, N. G.; Lia, L.; Judeh, Z.; Wang, Y.; Chong, K.; Loh, L. Fabrication of drug nanoparticles by evaporative precipitation of nanosuspension. Int. J. Pharm. 2010, 383, 285-292.
7. Liversidge, G. G.; Conzentino, P. In vivo evaluation of matrix pellets containing nanocrystalline ketoprofen. Int. J. Pharm. 1995, 20, 79-84.
8. Sharma, P.; Denny, W. A.; Garg, S. Effect of wet milling process on the solid state of indomethacin and simvastatin. Int. J. Pharm. 2009, 380, 40-48.
9. Trotta, M.; Gallarete, M.; Pattarino, F.; Morel, S. Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions. J. Controlled Release 2001, 76, 119-128.
10. Liversidge, G. G.; Conzentino, P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 1995, 125, 309-313.
11. Kayser, O.; Olbrich, C.; Yardley, V.; Kinderlen, A. F.; Croft, S. L. Formulation of amphotericin B as nanosuspension for oral administration. Int. J. Pharm. 2003, 254, 73-75.
12. Patel, R.; Patel, M. Preparation, characterization, and dissolution behavior of a solid dispersion of simvastatin with polyethylene glycol 4000 and Polyvinylpyrrolidone K30. J. Dispers. Sci. Techol. 2008, 29 (2), 193-204.
13. Hassan, M. A.; Suleiman, M. S.; Najib, N. M. Improvement of the in vitro dissolution characteristics of famotidine by inclusion in β-cyclodextrin. Int. J. Pharm. 1990; 58, 19-24.
14. Rania, H. F.; Mohammed, A. K. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: In vitro and in vivo evaluation. Eur. J. Pharm. Biopharm. 2008, 69, 993-1003.
15. Singh, B.; Chakkal, S.; Ahuja, N. Formulation and optimization of controlled release mucoadhesive tablets of atenolol using response surface methodology. AAPS PharmSciTech. 2006, 7, 19-28.
16. Patel, D. J.; Patel, J. K.; Pandya, V. M.; Patel, R. D. Effect of formulation variables on nanosuspension containing famotidine prepared by solvent evaporation technique. Int. J. Pharm. Sci. Nanotechnol. 2010, 4 (2), 707-713.
17. Zidan, A. S.; Sammourb, O. A.; Hammad, M. A.; Megrab, N. A.; Habib, M. J.; Khana M. A. Quality by design: Understanding the formulation variables of a cyclosporine a self-nanoemulsified drug delivery systems by Box-Behnken design and desirability function. Int. J. Pharm. 2007, 332, 55-63.